Patent classifications
C07C215/50
TRNA SYNTHETASE INHIBITORS
Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.
AMINATED LIGNIN-DERIVED COMPOUNDS AND USES THEREOF
The present invention relates to novel lignin-derived compounds and compositions comprising the same and their use as redox flow battery electrolytes. The invention further provides a method for preparing said compounds and compositions as well as a redox flow battery comprising said compounds and compositions. Additionally, an assembly for carrying out the inventive method is provided.
AMINATED LIGNIN-DERIVED COMPOUNDS AND USES THEREOF
The present invention relates to novel lignin-derived compounds and compositions comprising the same and their use as redox flow battery electrolytes. The invention further provides a method for preparing said compounds and compositions as well as a redox flow battery comprising said compounds and compositions. Additionally, an assembly for carrying out the inventive method is provided.
NOVEL COMPOUND AND PHARMACETICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING THEREOF
The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same.
##STR00001## in Chemical Formula 1, R.sub.1 and R.sub.2 are the same as defined in the specification.
NOVEL COMPOUND AND PHARMACETICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING THEREOF
The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same.
##STR00001## in Chemical Formula 1, R.sub.1 and R.sub.2 are the same as defined in the specification.
Redox Flow Battery Electrolytes
The present invention relates to novel combinations of redox active compounds for use as redox flow battery electrolytes. The invention further provides kits comprising these combinations, redox flow batteries, and method using the combinations, kits and redox flow batteries of the invention.
Redox Flow Battery Electrolytes
The present invention relates to novel combinations of redox active compounds for use as redox flow battery electrolytes. The invention further provides kits comprising these combinations, redox flow batteries, and method using the combinations, kits and redox flow batteries of the invention.
Redox Flow Battery Electrolytes
The present invention relates to novel combinations of redox active compounds for use as redox flow battery electrolytes. The invention further provides kits comprising these combinations, redox flow batteries, and method using the combinations, kits and redox flow batteries of the invention.
Nutrient Complexing Compositions
The invention provides compositions, systems and methods for controlling loss of nutrients and other substances from planting sites.
Nutrient Complexing Compositions
The invention provides compositions, systems and methods for controlling loss of nutrients and other substances from planting sites.